A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Exclusion Criteria

• •The following B-cell neoplasms: Burkitt lymphoma, lymphoblastic leukemia/lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia
• •Prior therapy containing an anti-PD-L1 agent or T-cell agonist
• •Current serious illness or medical condition including, but not limited to uncontrolled active infection
• •Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting MCLA-145
• •Prior ≥ Grade 3 immune-mediated AEs with anti-PD-1 therapy
• •History of any grade immune-mediated ocular AEs.
• •Known hypersensitivity or severe reaction to any component of MCLA-145 or formulation components
• •Participants who have active or inactive autoimmune disease or syndrome (eg, rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, inflammatory bowel disease) that has required systemic treatment in the past 2 years or who are receiving systemic therapy for an autoimmune or inflammatory disease (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)